Age- and Gender-Independent Association of XRCC1 Arg399Gln Polymorphism with Chronic Myeloid Leukemia by Abdalhabib EK, Jackson DE, Alzahrani B, Elfaki E, Hamza A, Mohamed Elasbali A, Alanazi F, Algarni A, Khider Ibrahim I, Saboor M

Subjects: Get full text

Pleural effusion as the initial manifestation of chronic myeloid leukemia: Report of a case with clinical and cytologic correlation by Paras Nuwal, Ramakant Dixit, Prateek Dargar, Jacob George

Subjects: “…Chronic myeloid leukemia; cytology; pleural effusion…”
Get full text

Isolated bone marrow sarcoidosis presenting as fever of unknown origin in a case of chronic myeloid leukemia by Ashok Grover, Saurabh Puri, Smriti Chabra, Meenal Mehta, Pravas Chand Mishra

Subjects: Get full text

Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia by Luma Al-Ali, Raad J. Al-Ani, Maysaa M. Saleh, Alaa M. Hammad, Duaa A. Abuarqoub, Bashaer Abu-Irmaileh, Abdallah Y. Naser, Manal M. Najdawi, Manal M. Abbas, Jamal Alyoussef Alkrad

Subjects: Get full text

Front-Line Tyrosine Kinase Inhibitors in Pediatric Chronic Myeloid Leukemia: A Study on Efficacy and Safety by Jae Won Yoo, Suejung Jo, Moon Bae Ahn, Seongkoo Kim, Jae Wook Lee, Myungshin Kim, Bin Cho, Nack-Gyun Chung

Subjects: Get full text

Extracellular vesicles in the Chronic Myeloid Leukemia scenario: an update about the shuttling of disease markers and therapeutic molecules by Simona Bernardi, Simona Bernardi, Olga Mulas, Silvia Mutti, Silvia Mutti, Alessandro Costa, Domenico Russo, Giorgio La Nasa

Subjects: “…Chronic Myeloid Leukemia…”
Get full text

Serum Calcium And Phosphateleveelsin Patients With Chronic Myeloid Leukemia Taking Different Dose of Tyrosine Kinase Inhibitors by Bassam Francis Matti, Shahla'a Fadhil Sabir, Maysaa Ali Abdul Khaleq, Marwah Hasan Al kaabi

Subjects: “…chronic myeloid leukemia…”
Get full text

Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia by Qing Wang, Zhi-Ping Jiang, Jing Zeng, Yan Zhu, Hua-Lin Cai, Da-Xiong Xiang, Qun He, Xiao-Liu Shi, An-Ni Zhong, Xie-Lan Zhao, Ping Xu

“…Purpose: We investigated the relationship between imatinib trough concentrations and genetic polymorphisms with efficacy of imatinib in Chinese patients with chronic myeloid leukemia (CML). Methods: There were 171 eligible patients. …”
Get full text

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™) by Martin Henkes, Heiko van der Kuip, Walter E Aulitzky

“…1Martin Henkes, 2Heiko van der Kuip, 1Walter E Aulitzky12nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch Hospital, Auerbachstr. 110, Stuttgart, Germany; 2Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstr. 112, Stuttgart, and University of Tuebingen, GermanyAbstract: Treatment options for chronic myeloid leukemia (CML) have changed dramatically during the last decades. …”
Get full text

Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors by Hong Chen, Yan Wen, Yun Zeng, Lie Lin, Bihong Sun, Hongqian Zhu, Huiqing He, Xiaotao Wang, Waiyi Zou, Caifeng Zheng, Liling Zheng, Jinxiong Huang, Liping Pang, Jixian Huang, Yuming Zhang, Haiqing Lin, Zelin Liu, Wanshou Zhu, Qiang Wang, Xuan Zhou, Xiaoli Liu, Hong Qu, Zhenfang Liu, Xin Du, Na Xu

Subjects: “…Chronic myeloid leukemia…”
Get full text

Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis by Olga Mulas, Giovanni Caocci, Brunella Mola, Giorgio La Nasa

“…Background: Off-target effects in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) are associated with cardiovascular toxicity. …”
Get full text

Evaluation of chronic myeloid leukemia patients and their molecular responses to tyrosine kinase inhibitors in Erbil city, Iraq by Kawa Muhamedamin Hasan

Subjects: “…Chronic myeloid leukemia…”
Get full text

Treatment Outcomes of Nilotinib as Second Line Therapy for Chronic Myeloid Leukemia Patients in Karbala Province of Iraq by Ahmed Mjali, Mustafa Majeed Obaid, Bassam Francis Matti, Nareen Tawfeeq Abbas

Subjects: “…chronic myeloid leukemia, nilotinib, second-line therapy, iraq…”
Get full text

Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase by Muriel Silva Moura, Thais Celi Lopes Benevides, Marcia Torresan Delamain, Gislaine Oliveira Duarte, Priscila Oliveira Percout, Maria Almeida Dias, Roberto Zulli, Carmino Antonio de Souza, Irene Lorand-Metze, Katia Borgia Barbosa Pagnano

“…Introduction: The incidence of grade 3–4 anemia was reported to be 3% with imatinib therapy for newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (CP). However, there are few data regarding the causes and the development of anemia after long-term treatment. …”
Get full text

A review on characterization of BCR – ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes by Benyam Zenebe, Helen Nigussie, Gurja Belay, Nigussie Seboka

Subjects: “…Chronic myeloid leukemia…”
Get full text

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia by Oliver Herrmann, Maja Kim Kuepper, Marlena Bütow, Ivan G. Costa, Iris Appelmann, Fabian Beier, Tom Luedde, Till Braunschweig, Steffen Koschmieder, Tim H. Brümmendorf, Mirle Schemionek

“…Abstract Background Expression of Bcr-Abl in hematopoietic stem cells is sufficient to cause chronic myeloid leukemia (CML) and tyrosine kinase inhibitors (TKI) induce molecular remission in the majority of CML patients. …”
Get full text

First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis by Chen KK, Du TF, Wu KS, Yang W

Subjects: “…chronic myeloid leukemia…”
Get full text

What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials? by Guilherme Rasia Bosi, Laura Maria Fogliatto, Tito Emilio Vanelli Costa, Kamila Castro Grokoski, Mariana Pinto Pereira, Nathan Bugs, Marco Kalil, Christina Fraga, Liane Esteves Daudt, Lucia Mariano da Rocha Silla

“…Methods: A retrospective cohort of 90 chronic myeloid leukemia patients in all phases of the disease treated with imatinib mesylate as their first TKI therapy, and with dasatinib or nilotinib as the next line of therapy. …”
Get full text

P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA by Valentin Garcia Gutierrez, Juan Carlos Hernandez-Boluda, Luis Felipe Casado Montero, M Teresa Gómez Casares, Rosa Ayala Diaz, Blanca Xicoy Cirici, Francisca Ferrer-Marín, Guillermo Ortí, Raquel De Paz Arias, Santiago Ossorio Prendes, Raúl Pérez López, Elvira Mora Castera, Concepcion Ruiz Nuño, Antonio Jimenez, Concepcion Boque Genovard, Magdalena Sierra, Joaquín Martinez-Lopez

Get full text

Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients by Massimo Breccia, Michele Baccarani, Gianantonio Rosti, Francesco Cottone, Laura Cannella, François Guilhot, Marco Vignetti, Fabio Efficace

Subjects: “…Chronic myeloid leukemia…”
Get full text